Navigation Links
Florastor(R) Receives ConsumerLab.com Certification
Date:3/11/2008

independent pharmacies. It can be purchased in bottles of 10 capsules for a suggested price of $9.95, or 50 capsules for a suggested price of $39.95. Florastor Kids is available in a box of 10 powder packets (which can be mixed with applesauce or beverages, including infant formula) for a suggested price of $11.95, or in a 20-packet box for a price of $19.95.

Visit http://www.florastor.com to find out where to purchase Florastor in your area. It is commonly found in the anti-diarrheal/stomach aid section, and can also be obtained by asking the pharmacist (many stores keep Florastor the product behind the counter). It can also be purchased online at http://www.newtimrx.com/florastor.html.

For more information on ConsumerLab.com testing, visit http://www.consumerlab.com.

(1) Saccharomyces boulardii: a valuable adjunct in recurrent Clostridium

difficile disease? (1995) WHO Drug Information; 9;(1); 15-16.


'/>"/>
SOURCE Florastor
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. DuraHeart(TM) LVAS Receives Conditional Approval for US Pivotal Trial
2. Vermillion Receives Award From the Society of Gynecologic Oncologists
3. Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM)
4. ActivBiotics Receives Orphan Drug Designation from the European Medicines Agency for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis Indication
5. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
6. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
8. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
9. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
10. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
11. Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... YORK, Dec. 15 Reportlinker.com announces ... available in its catalogue: ,, Boehringer ... http://www.reportlinker.com/p0168539/Boehringer-Ingelheim-GmbH-PharmaVitae-Profile.html ,, Introduction ,, ... performance for Boehringer Ingelheim in the Rx ... portfolio and pipeline analysis and assessment of ...
(Date:12/15/2009)... -- Reportlinker.com announces that a new ... its catalogue: ,, The Future ... to 2015, Competitive Benchmarking, Product Pipeline ... http://www.reportlinker.com/p0168102/The-Future-of-HIV-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html ,, Summary ... latest research "The Future of HIV ...
(Date:12/15/2009)... Belgium, Dec. 15 Ghent University Hospital ... world to pioneer radiotherapy treatments using arc therapy, ... and efficient RapidArc radiotherapy technology from Varian Medical ... patient was treated in just 75 seconds, over ... treatments. ,, "This treatment would have taken more ...
Breaking Medicine Technology:Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 2Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 3Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 4Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 5Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 6Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 7Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 4Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 5Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 6Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 7Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 8Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 9Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 10Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 11Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 12European Radiotherapy Pioneers Deliver First Varian RapidArc(TM) Treatment for Rectal Carcinoma Patient 2European Radiotherapy Pioneers Deliver First Varian RapidArc(TM) Treatment for Rectal Carcinoma Patient 3New Research Shows Over use of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist initiated Physician Intervention 6226 1New Research Shows Over use of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist initiated Physician Intervention 6226 2New Research Shows Over use of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist initiated Physician Intervention 6226 3Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology 6223 1Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology 6223 2Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology 6223 3Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology 6223 4Lexicon Announces Positive Phase 2 Results of LX1031 in Non Constipating Irritable Bowel Syndrome 6220 1Lexicon Announces Positive Phase 2 Results of LX1031 in Non Constipating Irritable Bowel Syndrome 6220 2Lexicon Announces Positive Phase 2 Results of LX1031 in Non Constipating Irritable Bowel Syndrome 6220 3Lexicon Announces Positive Phase 2 Results of LX1031 in Non Constipating Irritable Bowel Syndrome 6220 4Lexicon Announces Positive Phase 2 Results of LX1031 in Non Constipating Irritable Bowel Syndrome 6220 5
... Nov. 24 A new cancer treatment is,realizing ... treatment, a patient,s large, stage 4 tumor was ... of treatment, it no longer could be definitely,identified ... to nine months,after diagnosis. NeoPlas Innovation,s combination of ...
... moderate to severe acute pain and their health-care providers will ... Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD), announced that the ... for the relief of moderate to severe acute pain in ... , Tapentadol is a new centrally acting ...
Other Medicine Technology:New Cancer Treatment Shrinks Pancreatic Tumor 2FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 2FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 3FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 4FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 5FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 6
(Date:12/15/2009)... scientists have found the first potential immunological clue of ... the pandemic H1N1 virus. , The study analyzed ... 15 outpatients and 15 control subjects in 10 Spanish ... August 2009. Researchers from the Hospital Clinico Universitario de ... high levels of a molecule called interleukin 17 in ...
(Date:12/15/2009)... ATLANTA, GADecember 15, 2009Do good-looking people really benefit from ... researchers from the University of Georgia and the University ... to have more social relationships and therefore an increased ... and might be why we spend billions of dollars ... study, published in this month,s issue of Personal ...
(Date:12/15/2009)... Leading Workers, Compensation Carrier Confirms PMSI as Solution Provider ... ... Tampa, FL (Vocus) December 15, 2009 -- PMSI, ... providers of specialty products and services for the workers’ ... (KEMI) has decided to renew its pharmacy services (retail ...
(Date:12/15/2009)... deemed safer than wood fiber , , TUESDAY, Dec. 15 (HealthDay ... arm in a fall are much lower on playgrounds with ... new research has found. , Researchers at the Hospital for ... playground surfaces of either granite sand or engineered wood fiber. ... Medicine . , The risk of a broken arm resulting ...
(Date:12/15/2009)... study finds , , TUESDAY, Dec. 15 (HealthDay News) -- Tight ... with type 2 diabetes who have other medical problems, a ... in type 2 diabetes "has been a subject of controversy ... medicine at the University of California at Irvine, and lead ... the Annals of Internal Medicine . "Our work attempts ...
Breaking Medicine News(10 mins):Health News:First immunological clue to why some H1N1 patients get very ill or die 2Health News:The importance of attractiveness depends on where you live 2Health News:KEMI Renews Contract With PMSI 2Health News:Tighter Blood Sugar Control Not Best for Some Diabetics 2Health News:Tighter Blood Sugar Control Not Best for Some Diabetics 3
... EntreMed, Inc.,(Nasdaq: ENMD ) a clinical-stage ... and inflammatory diseases,announced today that James S. Burns, ... overview at the Acumen BioFin Rodman & Renshaw ... New York Palace Hotel in,New York, November 5-7, ...
... BPUR ) announced today that the trading symbol ... to BPUR at the open of the market on,Wednesday, ... OTCBB,will revert to the following ticker symbols: BPREW reverting ... BPURL. Biopure Corporation Biopure Corporation develops, manufactures ...
... FRANCISCO, Calif., Oct. 31 Anesiva,Inc. (Nasdaq: ANSV ... chief executive officer, will present at the following events ... November 6, 2007 3:45 p.m. ET ... Healthcare Conference November 27, 2007 4:30 p.m. ...
... QUEBEC CITY, Oct. 31 /PRNewswire-FirstCall/ - AEterna Zentaris ... focused on,endocrine therapy and oncology, will announce its ... open on Wednesday, November,7, 2007. The Company will ... results on the same day at 10:00 a.m. ...
... NORTHAMPTON, Mass., Oct. 31 Physicians ... posts to Healthcommunities.com,Inc.,s healthchannels forum,( http://www.healthcommunities.com/health/forums.shtml ... physician post was submitted to the ... hosted and maintained by,Healthcommunities.com, Inc. (HC), ...
... ALTH ), a biopharmaceutical company focused on,the development ... cancer, today announced that Paul L. Berns, President and,CEO, ... BioFin Rodman &,Renshaw Conference in New York. The ... on,Tuesday, November 6, 2007. There will be a live ...
Other Medicine News:Health News:EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference 2Health News:Biopure's Stock Symbol Reverts to BPUR 2Health News:Anesiva Announces Upcoming Webcasts and Conference Participation 2Health News:Free Site Offering Patient-Physician Dialog Reaches Milestone 2Health News:Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: